Posted by Michael Wonder on 10 Dec 2021
Cytokinetics announces receipt of breakthrough therapy designation from FDA for aficamten
9 December 2021 - FDA granted designation for the treatment of symptomatic obstructive hypertrophic cardiomyopathy Based on results of REDWOOD-HCM.
Cytokinetics today announced that the U.S. FDA has granted breakthrough therapy designation for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Aficamten is a next generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy.
